The CTNG testing market is projected to be worth US$ 1.8 billion in 2024. The market is anticipated to reach US$ 3.9 billion by 2034. The market is further expected to surge at a CAGR of 8.0% during the forecast period 2024 to 2034.
Key Market Trends and Highlights
The expansion of healthcare infrastructure, particularly in emerging economies, creates opportunities for increased access to CTNG testing services, leading to market expansion.
| Attributes | Key Insights |
|---|---|
| CTNG Testing Market Estimated Size in 2024 | US$ 1.8 billion |
| Projected Market Value in 2034 | US$ 3.9 billion |
| Value-based CAGR from 2024 to 2034 | 8.0% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The scope for CTNG testing rose at a 10.2% CAGR between 2019 and 2023. The global market is anticipated to grow at a moderate CAGR of 8.0% over the forecast period 2024 to 2034.
The CTNG testing Market witnessed steady growth during the historical period, driven by factors such as increasing awareness about STIs, advancements in diagnostic technologies, and expansion of healthcare infrastructure.
Significant advancements in CTNG testing technologies, including the introduction of multi parameter CT/NG NAATs and point of care testing solutions, enhanced the accuracy, sensitivity, and accessibility of diagnostic tests.
The rising incidence of chlamydia and gonorrhea infections globally, coupled with the emergence of antibiotic resistant strains, underscored the need for effective screening and detection methods, driving market demand.
The forecast period is expected to witness continued technological innovations in CTNG testing, including the development of next generation molecular assays, advanced point of care devices, and integrated diagnostic platforms, driving market expansion.
The increasing demand for point of care testing solutions for STIs, driven by the need for rapid and convenient diagnostics in diverse healthcare settings, is expected to fuel market growth during the forecast period.
The expansion of telemedicine platforms and remote testing services is anticipated to facilitate broader access to CTNG testing, particularly in underserved rural areas and resource limited settings, contributing to market expansion.
Increasing awareness about sexually transmitted infections, including chlamydia and gonorrhea, among the population drives the demand for CTNG testing.
Principal Consultant
The cost associated with CTNG testing procedures, including diagnostic kits, laboratory equipment, and personnel training, can be prohibitive for healthcare providers and patients, hindering widespread adoption and accessibility.
The below table showcases revenues in terms of the top 5 leading countries, spearheaded by Korea and the United Kingdom. The countries are expected to lead the market through 2034.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 8.3% |
| The United Kingdom | 9.3% |
| Japan | 9.0% |
| China | 8.7% |
| Korea | 9.8% |
The CTNG testing market in the United States expected to expand at a CAGR of 8.3% through 2034. The country has seen a rise in the prevalence of chlamydia and gonorrhea infections, particularly among sexually active individuals and high risk populations, driving the demand for CTNG testing services to address the public health burden of these STIs.
Stringent regulatory requirements set by organizations such as the Food and Drug Administration mandate the need for comprehensive CTNG testing as part of regulatory approvals for medical devices, diagnostics, and pharmaceutical products, fostering market growth.
The CTNG testing market in the United Kingdom is anticipated to expand at a CAGR of 9.3% through 2034. The implementation of national screening programs, such as the National Chlamydia Screening Program and the National Gonorrhea Screening Programme, promotes routine CTNG testing among sexually active individuals, contributing to increased testing rates and early detection of infections.
Government funding and support for STI prevention, control, and screening initiatives, including investments in sexual health services and public health campaigns, drive the implementation of CTNG testing services and raise public awareness about the importance of STI screening and treatment.
CTNG testing trends in China are taking a turn for the better. An 8.7% CAGR is forecast for the country from 2024 to 2034. The expansion of healthcare infrastructure in China, including the establishment of sexual health clinics, community health centers, and primary care facilities, facilitates access to CTNG testing services for individuals seeking sexual health care, particularly in urban and rural areas.
Increasing awareness about STIs and sexual health issues, driven by educational initiatives, media campaigns, and community outreach programs, encourages individuals to seek CTNG testing services and promotes safe sexual practices, reducing the spread of STIs.
The CTNG testing market in Japan is poised to expand at a CAGR of 9.0% through 2034. Ongoing advancements in CTNG testing technologies, including nucleic acid amplification tests, molecular assays, and point of care testing devices, enhance the accuracy, sensitivity, and accessibility of testing services, driving market adoption and utilization.
Increased investments by private sector companies in STI diagnostics and healthcare services, coupled with market liberalization policies, stimulate competition, innovation, and market growth in the market.
The CTNG testing market in Korea is anticipated to expand at a CAGR of 9.8% through 2034. The emergence of antibiotic resistant strains of chlamydia and gonorrhea in Korea highlights the importance of early detection and appropriate treatment, driving the demand for CTNG testing services to guide therapeutic decisions and prevent the spread of drug resistant infections.
Increasing emphasis on sexual health education in schools, universities, and community organizations raises awareness about STIs, promotes safe sexual practices, and encourages regular STI screening among young people and at risk populations, driving the demand for CTNG testing services.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below table highlights how assays and kits segment is projected to lead the market in terms of product, and is expected to account for a CAGR of 7.7% through 2034. Based on test type, the laboratory segment is expected to account for a CAGR of 7.5% through 2034.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Assays and Kits | 7.7% |
| Laboratory | 7.5% |
Based on product, the assays and kits segment is expected to continue dominating the CTNG testing market. Ongoing advancements in assay and kit technologies, including nucleic acid amplification tests, polymerase chain reaction, and loop mediated isothermal amplification, enhance the sensitivity, specificity, and speed of CTNG detection, driving demand for assay and kit products.
Assays and kits offer high levels of accuracy and reliability in detecting chlamydia and gonorrhea infections, making them essential tools for healthcare providers and laboratories conducting routine screening, diagnosis, and surveillance programs.
Assays and kits are designed to be user friendly, with standardized protocols and procedures that simplify sample collection, processing, and interpretation, enabling healthcare professionals to perform CTNG testing efficiently in diverse clinical and laboratory settings.
In terms of test type, the laboratory segment is expected to continue dominating the CTNG testing market, attributed to several key factors. Laboratory based tests offer high levels of accuracy and precision in detecting chlamydia and gonorrhea infections, making them the gold standard for diagnosis and confirmation of STIs.
Laboratories have the infrastructure, equipment, and expertise to perform comprehensive CTNG testing, including nucleic acid amplification tests, culture based methods, and antimicrobial susceptibility testing, enabling thorough assessment and characterization of STI pathogens.
Laboratories offer specialized testing services, such as genotyping, serotyping, and molecular epidemiology, to identify strain variations, antimicrobial resistance patterns, and transmission dynamics of chlamydia and gonorrhea pathogens, facilitating targeted treatment and public health interventions.
The competitive landscape of the CTNG testing market is characterized by the presence of several established players, emerging companies, and innovative startups competing to gain market share and meet the growing demand for accurate, reliable, and accessible testing solutions for chlamydia and gonorrhea infections.
Company Portfolio
| Attribute | Details |
|---|---|
| Estimated Market Size in 2024 | US$ 1.8 billion |
| Projected Market Valuation in 2034 | US$ 3.9 billion |
| Value-based CAGR 2024 to 2034 | 8.0% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in US$ Billion |
| Key Regions Covered |
|
| Key Market Segments Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
The CTNG testing market is projected to reach a valuation of US$ 1.8 Billion in 2024.
The CTNG testing industry is set to expand by a CAGR of 8.0% through 2034.
The CTNG testing market is forecast to reach US$ 3.9 Billion by 2034.
Korea is expected to be the top performing market, exhibiting a CAGR of 9.8% through 2034.
Assays and kits segment is preferred, and is expected to account for a CAGR of 7.7% through 2034.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2024 to 2034 5.3.1. Assays & kits 5.3.2. Instruments/Analyzers 5.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Test Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2024 to 2034 6.3.1. Laboratory 6.3.2. Point-of-care testing 6.4. Y-o-Y Growth Trend Analysis By Test Type, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Test Type, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2024 to 2034 7.3.1. INAAT 7.3.2. PCR 7.3.3. Immunodiagnostics 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By Technology, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Technology, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Product 9.2.3. By Test Type 9.2.4. By Technology 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By Test Type 9.3.4. By Technology 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Product 10.2.3. By Test Type 10.2.4. By Technology 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By Test Type 10.3.4. By Technology 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Product 11.2.3. By Test Type 11.2.4. By Technology 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By Test Type 11.3.4. By Technology 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Product 12.2.3. By Test Type 12.2.4. By Technology 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By Test Type 12.3.4. By Technology 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Product 13.2.3. By Test Type 13.2.4. By Technology 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By Test Type 13.3.4. By Technology 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Product 14.2.3. By Test Type 14.2.4. By Technology 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By Test Type 14.3.4. By Technology 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Product 15.2.3. By Test Type 15.2.4. By Technology 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product 15.3.3. By Test Type 15.3.4. By Technology 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Product 16.1.2.2. By Test Type 16.1.2.3. By Technology 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Product 16.2.2.2. By Test Type 16.2.2.3. By Technology 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Product 16.3.2.2. By Test Type 16.3.2.3. By Technology 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Product 16.4.2.2. By Test Type 16.4.2.3. By Technology 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Product 16.5.2.2. By Test Type 16.5.2.3. By Technology 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Product 16.6.2.2. By Test Type 16.6.2.3. By Technology 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Product 16.7.2.2. By Test Type 16.7.2.3. By Technology 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Product 16.8.2.2. By Test Type 16.8.2.3. By Technology 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Product 16.9.2.2. By Test Type 16.9.2.3. By Technology 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Product 16.10.2.2. By Test Type 16.10.2.3. By Technology 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Product 16.11.2.2. By Test Type 16.11.2.3. By Technology 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Product 16.12.2.2. By Test Type 16.12.2.3. By Technology 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Product 16.13.2.2. By Test Type 16.13.2.3. By Technology 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Product 16.14.2.2. By Test Type 16.14.2.3. By Technology 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Product 16.15.2.2. By Test Type 16.15.2.3. By Technology 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Product 16.16.2.2. By Test Type 16.16.2.3. By Technology 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Product 16.17.2.2. By Test Type 16.17.2.3. By Technology 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Product 16.18.2.2. By Test Type 16.18.2.3. By Technology 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Product 16.19.2.2. By Test Type 16.19.2.3. By Technology 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Product 16.20.2.2. By Test Type 16.20.2.3. By Technology 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Product 16.21.2.2. By Test Type 16.21.2.3. By Technology 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Product 16.22.2.2. By Test Type 16.22.2.3. By Technology 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Product 16.23.2.2. By Test Type 16.23.2.3. By Technology 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Product 17.3.3. By Test Type 17.3.4. By Technology 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. F. Hoffmann-La Roche Ltd. (Switzerland) 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Hologic, Inc. (USA) 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Thermo Fisher Scientific Inc. (USA) 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Abbott Laboratories (USA) 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Bio-Rad Laboratories, Inc. (USA) 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Siemens Healthineers AG (Germany) 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Danaher (USA) 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Becton 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Dickinson and Company (USA) 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
CTNG Testing Market
